Company: RPTX
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001193125-25-283336
Chunk: 8

Company: Repare Therapeutics Inc.
Filing Date: 2025-11-14
Form: 10-Q
Item: Item 6
Chunk 8
---
Incorporated by Reference

     ExhibitNumber
      
     Description
      
     ScheduleForm
      
     FileNumber
      
     Exhibit
      
     Filing Date

     3.1
      
     Articles of Continuance of Repare Therapeutics Inc.
      
     8-K
      
     001-39335
      
     3.1
      
     June 23, 2020

     3.2
      
     Amended and Restated Bylaws of Repare Therapeutics Inc.
      
     8-K
      
     001-39335
      
     3.2
      
     June 23, 2020

     10.1†*
      
     Collaboration and License Agreement by and between the registrant Repare Therapeutics Inc. and Debiopharm International SA dated July 14, 2025.

     31.1*
      
     Certification of Principal Executive Officer and Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

     32.1**
      
     Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

     101.INS*
      
     Inline XBRL Instance Document–the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the Inline XBRL document

     101.SCH*
      
     Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents

     104
      
     Inline Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)

* Filed herewith.

** This certification is being furnished solely to accompany this Quarterly Report on Form 10-Q pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing of the registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of